Home Finance A Bet That Definitely Worked; But Persistence Needed: Moleculin Biotech Inc. (MBRX)

A Bet That Definitely Worked; But Persistence Needed: Moleculin Biotech Inc. (MBRX)

Moleculin Biotech, Inc., (Nasdaq: MBRX) shares are trade -2.84% to $4.78. Based on the relationship between its 200-day and 20-day major moving averages, Moleculin Biotech Inc. (MBRX) has been in rally mode. MBRX shares have risen 4.72% in the past 30 days. Stocks have declined -7.98% over the trailing 12 months, outperforming the market by 262.16%. Its performance trailed competitor brands by 30.32 percent.

 Corporate Details


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Moleculin Biotech, Inc. develops vaccines to treat non-communicable diseases such as viral hepatitis and HIV.

Meanwhile, in the global biopharmaceutical industry, Catalyst offers highly customizable clinical research solutions, including Catalyst Flex and Catalyst Oncology. Through offices in the US and EU and over 500 staff, the company provides multitherapeutic global sourcing and functional services through Catalyst Flex, and a comprehensive oncology CRO service through Catalyst Oncology.

What just happened

Moleculin Biotech, Inc., (Nasdaq: MBRX) announced today that it has entered into a research agreement with Catalyst Clinical Research, Inc., a contract research organization, to manage its US clinical trial to study Annamycin’s ability to treat sarcomas that have spread to the lungs.

Approximately 130,000 incident sarcoma cases are reported every year through soft tissue sarcomas. The removal of many sarcomas can be accomplished by surgery, but as many as 20% to 50% will end up metastasizing to the lungs, in which case treatment becomes challenging.

Anthracycline doxorubicin, or Adriamycin, is the primary chemotherapy regimen used if tumors have spread to the lungs if surgical removal is not possible. Although 10 to 30% of patients with sarcoma lung metastases initially respond to doxorubicin, many will relapse, leaving them with no other option for treatment. Several anthracycline drugs, including doxorubicin, carry inherent cardiotoxicity, which further limits treatment options.

Approximately 34 times the concentration of doxorubicin has been found in the lungs of animals treated with annamycin. Moreover, Annamycin has also showed an absence of cardiotoxicity during human clinical trials focusing on acute myeloid leukemia, therefore it will not have to undergo the same dose restrictions imposed on doxorubicin.

Conclusion

Experts agree that drug development is at its peak in our lifetimes. Science is providing new insights into the prevention and treatment of diseases previously unknown. If approved by authorities, the pharmaceutical industry is likely to provide investors with huge returns.

 

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Why Is BTZI Stock Increasing Today?

The stock price of BOTS, Inc. (OTCPink: BTZI) has been rising more than 7% today and was buoying at $0.1266 at the last check....

Why Has The KBSF Stock Price Gained 10% In Last Session?

As of Friday's normal trading session, the price of KBS Fashion Group Limited (NASDAQ: KBSF) rose $0.26 or 9.96% to conclude at $2.87. KBS...

Why Royal Bank of Canada (RY) stock plummeted in after-hours on Friday?

Royal Bank of Canada (RY) stock lost 64.36% in the extended hour trading session on Friday, April 16, 2021. The RY stock gained merely...

Why Did The CMCL Stock Rise By 8% In Last Trading?

Caledonia Mining Corporation Plc (NYSE: CMCL) gained 8.91% during the trading session on Thursday. The share price reached a low of $13.70 and a...

Why Progyny Inc (PGNY) stock gained on Thursday, April 15?

Progyny Inc (PGNY) stock gained 7.31% in the after-hours session on Thursday, April 15, 2021, after it gained 0.94% in the early session.  PGNY...

Is This Why The APLD Stock Skyrocketed Last Trading?

Applied Science Products, Inc. (OTCPK: APLD) closed at $0.635 and experienced a 215.92% increase on Friday. A total of 2.07M shares of Applied Science...

The CRSS Stock Increased 82% In The Last Session Due To What?

Stock of Crossroads Systems, Inc. (OTCQX: CRSS) gained 81.82% or $18.00 in Friday's trading session, closing the day at $40.00 a share. Crossroads Systems...

How Did The ZVO Stock Appreciate 9% In The Last Trading Session?

Zovio Inc (NASDAQ: ZVO) normally sees about 413.34K shares traded on a regular business day but on a Friday it saw a bit higher...

Related News

Acasti Pharma Inc. (ACST) stock is Bearish after this big Update

Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST) stock plunged more than 22% in the premarketing today after the news that, since obtaining...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.